---
layout: default
title: Fluorometholone
parent: 僅模型預測 (L5)
nav_order: 722
evidence_level: L5
indication_count: 10
---

# Fluorometholone
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Fluorometholone: From Ocular Inflammation to Postinfectious Vasculitis

## One-Sentence Summary

> Fluorometholone is a topical, low-penetration ophthalmic corticosteroid; formal original-indication and mechanism-of-action data are currently missing from this evidence pack (flagged as data gaps).
> The TxGNN model's top-ranked prediction is **Postinfectious Vasculitis**, but this candidate has **0 clinical trials** and **0 publications** — the score is model-only with no mechanistic or clinical support.
> Two other candidates in this same evaluation batch (post-bacterial disorder, punctate epithelial keratoconjunctivitis) carry real clinical-trial and literature evidence and are far stronger candidates than the top-ranked one; see the note below.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not on file — no approved license/indication text available (see Data Gaps) |
| Predicted New Indication | Postinfectious Vasculitis |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 (model prediction only) |
| US/Local Market Status | 未上市 (Not Marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged **DG002, High severity** in this evidence pack). Based on the repurposing-rationale text accompanying these predictions, fluorometholone is consistently characterized as a **topical, low-penetration ophthalmic corticosteroid** — a class used for steroid-responsive ocular surface and anterior-segment inflammation, not for systemic anti-inflammatory or vasculitis treatment.

For the top-ranked prediction, **postinfectious vasculitis**, the evidence pack's own analysis states there is no pharmacological basis or route-of-administration support for this indication: vasculitis is a systemic disease, while fluorometholone is a topical ocular agent with negligible systemic exposure. The 99.91% TxGNN score reflects the model's internal ranking only, with zero clinical trials and zero literature backing it (clinicaltrials.gov, ICTRP, and PubMed searches on 2026-04-21 all returned 0 results). This should be treated as a hypothesis-generating signal only, not an evidence-supported repurposing lead.

**Note on stronger candidates in this batch:** This evidence pack evaluated 10 candidate indications for fluorometholone. Two ranked lower by TxGNN score but carry materially better evidence and are worth separate follow-up: **post-bacterial disorder** (rank 2, L3, "Research Question" — includes a completed trachomatous entropion perioperative trial and an upcoming Phase 2 bacterial corneal ulcer trial, both ophthalmic and mechanistically coherent) and **punctate epithelial keratoconjunctivitis** (rank 6, L3, "Proceed with Guardrails" — supported by 2 relevant reviews, consistent with fluorometholone's established anti-inflammatory use in post-keratoconjunctivitis sequelae, with a flagged risk of steroid use masking active infection).

---

## Clinical Trial Evidence

Currently no related clinical trials registered for Postinfectious Vasculitis.

---

## Literature Evidence

Currently no related literature available for Postinfectious Vasculitis.

---

## US Market Information

No marketing authorizations on file. Fluorometholone's local regulatory status is recorded as **未上市 (Not Marketed)** with 0 licenses in this evidence pack.

---

## Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-interaction data are all currently unavailable — DDI query returned "not_found," and TFDA label warnings/contraindications are flagged **DG001, Blocking severity**, meaning this candidate cannot yet pass initial safety screening.)

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (postinfectious vasculitis) has no clinical trials, no literature, and no mechanistic plausibility per the evidence pack's own analysis — it is a pure model-score artifact. Separately, a Blocking-severity data gap (missing TFDA label warnings/contraindications) prevents this drug from clearing initial safety screening (S1) for any indication.

**To proceed, the following is needed:**
- TFDA package-insert warnings/contraindications (source: TFDA official site, PDF parsing) — required to clear S1 safety screening
- Mechanism-of-action data from DrugBank API — required for mechanistic-relevance analysis
- If pursuing a repurposing candidate for this drug, consider redirecting evaluation toward **post-bacterial disorder** or **punctate epithelial keratoconjunctivitis**, which already have trial/literature support within this same batch, rather than the top-ranked but evidence-free postinfectious vasculitis candidate
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

